{"meta":{"query_hash":"78c2101363ae","filters":{"venue":"Clinical Lymphoma & Myeloma"},"cohort_total":13,"direct_labels_cover":0,"predictions_cover":13,"exported":13,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/78c2101363ae","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Lymphoma+%26+Myeloma"},"results":[{"id":"W1965861190","doi":"10.3816/clm.2006.s.003","title":"Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach","year":2006,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"International Prognostic Index; Rituximab; Medicine; Diffuse large B-cell lymphoma; Context (archaeology); Oncology; Prednisone; Lymphoma; Vincristine; Internal medicine; CHOP; Cyclophosphamide; Clinical trial; Intensive care medicine; Chemotherapy; Biology","score_opus":0.06659608710929593,"score_gpt":0.373539151332449,"score_spread":0.3069430642231531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965861190","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007285988,0.97865546,0.00006229872,0.000032010663,0.0006054322,0.0038003088,0.0014992406,0.00026494043,0.007794349],"genre_scores_gemma":[0.006988157,0.98229915,0.0025072882,0.00012764355,0.0010945606,0.0013623389,0.0033255178,0.00032438562,0.0019709382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9902066,0.0010326155,0.004373487,0.0021685867,0.0009449215,0.0012738112],"domain_scores_gemma":[0.99054986,0.0026369889,0.0028076319,0.0028404733,0.00024954922,0.0009154714],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006422851,0.0019098136,0.009312323,0.00050564104,0.00022866062,0.00006767876,0.00055761135,0.0018746424,0.00007401837],"category_scores_gemma":[0.0003025901,0.0012847857,0.0070508616,0.00085225474,0.0004954501,0.000069720074,0.00017050756,0.00019449565,0.0005612267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002740469,0.13896988,0.0074913613,0.0076997713,0.001427938,0.0007893301,0.000018224917,2.8024138e-7,5.4810595e-8,0.00009372751,0.002341434,0.840894],"study_design_scores_gemma":[0.07153158,0.0038097713,0.016152287,0.0034049193,0.015251763,0.00030903704,0.0000127236135,0.00012756283,0.000012973651,0.000014226111,0.8884491,0.000924069],"about_ca_topic_score_codex":0.0003474243,"about_ca_topic_score_gemma":0.000012937336,"teacher_disagreement_score":0.8861076,"about_ca_system_score_codex":0.001991736,"about_ca_system_score_gemma":0.0032173048,"threshold_uncertainty_score":0.9994211},"labels":[],"label_agreement":null},{"id":"W1983399256","doi":"10.3816/clm.2007.s.005","title":"The Challenges of Targeting Chronic Myeloid Leukemia Stem Cells","year":2007,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; University of British Columbia; Canada Research Chairs; Leukemia and Lymphoma Society of Canada; Michael Smith Health Research BC; Terry Fox Foundation; Cancer Research Society","keywords":"Myeloid leukemia; Stem cell; Cancer research; Leukemia; Medicine; Biology; Immunology; Cell biology","score_opus":0.09710067136416807,"score_gpt":0.3856242570326927,"score_spread":0.28852358566852465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983399256","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005684561,0.9883473,0.00000835614,0.000093093506,0.002265458,0.002536958,0.00005194864,0.00021985623,0.005908587],"genre_scores_gemma":[0.00029284036,0.9924697,0.0003806176,0.00008805352,0.0031122207,0.00018592483,0.00009436215,0.0003446279,0.0030316266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98902833,0.0009127938,0.0055052876,0.0017421626,0.0012270262,0.0015843721],"domain_scores_gemma":[0.98536485,0.008002576,0.0027631645,0.0027591255,0.00034367025,0.00076658494],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004178631,0.0014371513,0.0063001867,0.0002800379,0.00033894638,0.000054377044,0.0013325799,0.0021144005,0.000114096794],"category_scores_gemma":[0.0006119753,0.00091400027,0.0035261214,0.0006656615,0.0011338491,0.000093886236,0.0006405423,0.0012977532,0.0011349873],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012816345,0.00027585888,0.000018823739,0.016101593,0.0016275931,0.00039316,0.00003471363,2.6094088e-7,0.0000026667806,0.00065767043,0.0025931092,0.9781664],"study_design_scores_gemma":[0.0037533692,0.0010657872,0.00040546613,0.020718131,0.002983588,0.000429913,0.000079300225,0.000025059042,0.00007368909,0.00003482997,0.9697247,0.0007061299],"about_ca_topic_score_codex":0.000039843064,"about_ca_topic_score_gemma":0.000026894513,"teacher_disagreement_score":0.97746027,"about_ca_system_score_codex":0.008188662,"about_ca_system_score_gemma":0.011248783,"threshold_uncertainty_score":0.9998378},"labels":[],"label_agreement":null},{"id":"W1997044577","doi":"10.3816/clm.2009.n.003","title":"Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Cancerfonden; McMaster University","keywords":"Monoclonal gammopathy of undetermined significance; Macroglobulinemia; Waldenstrom macroglobulinemia; Gammopathy; Medicine; Immunology; Immunoglobulin M; Polyclonal antibodies; Antibody; Etiology; Population; Monoclonal; Pathology; Multiple myeloma; Immunoglobulin G; Monoclonal antibody; Lymphoma","score_opus":0.05563567867414868,"score_gpt":0.3574969234013634,"score_spread":0.3018612447272147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997044577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918654,0.0007510817,0.00040648974,0.0031879398,0.00027781617,0.001021615,0.00008321634,0.00007483552,0.0023315812],"genre_scores_gemma":[0.99014896,0.000076447206,0.0068492265,0.0013047624,0.000816718,0.000031782416,0.000034639033,0.000054371856,0.00068309007],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946877,0.00022966342,0.0021617713,0.00092894223,0.0011812153,0.0008107098],"domain_scores_gemma":[0.9932013,0.0038248287,0.00058458047,0.0011584248,0.00047625368,0.0007545708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018361816,0.00045930906,0.0012743584,0.0002479144,0.00017897847,0.00004117303,0.00060565345,0.00044688536,0.00006652704],"category_scores_gemma":[0.0056275013,0.00035037898,0.0004585523,0.000891456,0.00086396316,0.000111211535,0.0002803106,0.00047463577,0.000043785945],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015174349,0.003479225,0.27988905,0.0006917435,0.00047913176,0.0014748242,0.0016322598,0.00026062553,0.032703638,0.012552772,0.005372003,0.64629036],"study_design_scores_gemma":[0.01722147,0.0026709267,0.96009666,0.0005724313,0.0002327671,0.00198205,0.00026520636,0.010120379,0.004242905,0.0009583187,0.0012183768,0.0004185154],"about_ca_topic_score_codex":0.00031441532,"about_ca_topic_score_gemma":0.00006233042,"teacher_disagreement_score":0.6802076,"about_ca_system_score_codex":0.0015175209,"about_ca_system_score_gemma":0.005933968,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W1999005132","doi":"10.3816/clm.2009.n.001","title":"Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; International Waldenstrom's Macroglobulinemia Foundation","keywords":"Waldenstrom macroglobulinemia; Macroglobulinemia; Medicine; Immunology; Lymphoma; Multiple myeloma","score_opus":0.0522128022844153,"score_gpt":0.42570897067548746,"score_spread":0.37349616839107214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999005132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97293264,0.004146691,0.000029572402,0.016204195,0.00056884636,0.0010708763,0.00007749737,0.000054604556,0.0049150614],"genre_scores_gemma":[0.98873466,0.005879846,0.0006269907,0.0024291999,0.0015320135,0.00007252073,0.00018496692,0.000029731918,0.0005100598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9955332,0.00041397839,0.0016797328,0.0009884428,0.0007600792,0.00062451116],"domain_scores_gemma":[0.9935169,0.004219574,0.00048261904,0.0013390104,0.00019941521,0.00024244562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010950166,0.00043615137,0.0010080058,0.000112252696,0.0001245213,0.00006075552,0.0007409191,0.00047808312,0.00013172456],"category_scores_gemma":[0.0020497758,0.00023845231,0.00038224488,0.00040076365,0.0009058983,0.000103456994,0.00016132275,0.00038999316,0.000047963193],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002777645,0.0014303768,0.059349336,0.000011959621,0.00016342335,0.0039685587,0.000397276,0.000010959545,0.00011816436,0.00059433474,0.0017497727,0.9294282],"study_design_scores_gemma":[0.04299624,0.0041274563,0.81287676,0.0006887246,0.00031345512,0.006391182,0.0011874972,0.0033317867,0.00066736795,0.003584287,0.12328666,0.00054858247],"about_ca_topic_score_codex":0.0006500637,"about_ca_topic_score_gemma":0.0003085819,"teacher_disagreement_score":0.9288796,"about_ca_system_score_codex":0.0024486377,"about_ca_system_score_gemma":0.0018331043,"threshold_uncertainty_score":0.9723803},"labels":[],"label_agreement":null},{"id":"W2029070773","doi":"10.3816/clm.2009.s.032","title":"Molecular and Genetic Bases of Myeloproliferative Disorders: Questions and Perspectives","year":2009,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; AstraZeneca","keywords":"Essential thrombocythemia; Myelofibrosis; Polycythemia vera; Myeloproliferative Disorders; Loss of heterozygosity; Mutation; Pathogenesis; Genetics; Epigenetics; Biology; Exon; Bioinformatics; Medicine; Gene; Immunology; Allele","score_opus":0.05432203405575678,"score_gpt":0.3835875530794639,"score_spread":0.32926551902370715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029070773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01985789,0.976579,0.000033577053,0.00069289224,0.000086375585,0.0018712583,0.000105224775,0.00005761139,0.00071618485],"genre_scores_gemma":[0.012008186,0.98429984,0.0026593953,0.00026518374,0.00023375492,0.00027645068,0.000075867436,0.00007620782,0.00010512683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960032,0.00056992145,0.0015374317,0.0011717778,0.00033841003,0.00037923042],"domain_scores_gemma":[0.9966655,0.0014266715,0.0005732054,0.00061356154,0.00023831264,0.00048276866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025986144,0.0007728784,0.0036105292,0.00025293167,0.0001350897,0.000051368184,0.00013239609,0.0005710298,0.00005094456],"category_scores_gemma":[0.001054887,0.0005709728,0.00074839406,0.00031252686,0.00082752533,0.00008155802,0.00013915864,0.00030441734,0.000018475735],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006576116,0.001256491,0.0035629054,0.0024540108,0.0009033045,0.00022441517,0.00013075185,1.1901959e-7,5.997353e-7,0.002385525,0.0001380201,0.9888781],"study_design_scores_gemma":[0.005615958,0.006791901,0.3435467,0.026186295,0.009837684,0.0017263342,0.00030015467,0.000036367677,0.000023868397,0.0015370792,0.60301924,0.0013784094],"about_ca_topic_score_codex":0.000025286841,"about_ca_topic_score_gemma":0.000014848843,"teacher_disagreement_score":0.9874997,"about_ca_system_score_codex":0.00012354378,"about_ca_system_score_gemma":0.0006978006,"threshold_uncertainty_score":0.9996742},"labels":[],"label_agreement":null},{"id":"W2033238287","doi":"10.3816/clm.2009.n.047","title":"von Hippel–Lindau Methylation Status in Patients with Multiple Myeloma: A Potential Predictive Factor for the Development of Bone Disease","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Bone health and treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Disease; Medicine; Methylation; Oncology; Cancer research; Internal medicine; Pathology; Biology; Genetics; Gene","score_opus":0.026023887822227466,"score_gpt":0.3245251999379395,"score_spread":0.298501312115712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033238287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949714,0.00028022393,0.0013266208,0.00039941515,0.00022412319,0.0025098058,0.00021525813,0.000043152613,0.000030030826],"genre_scores_gemma":[0.99502045,0.00001970376,0.0040469365,0.00032649824,0.00008278802,0.000116311734,0.0002957052,0.000028199935,0.000063411986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718714,0.00010762335,0.0012111872,0.00047150868,0.00049892254,0.00052360917],"domain_scores_gemma":[0.997751,0.00063986605,0.00040124782,0.00037969495,0.00029112847,0.0005370722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035306317,0.00026017334,0.0006171905,0.0001135173,0.00014954866,0.000011342965,0.00008570422,0.0001681177,0.000017406172],"category_scores_gemma":[0.00079558586,0.00016395675,0.0001816441,0.0002241414,0.00012635482,0.00010758661,0.000032942084,0.00013196678,0.000010119357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01554811,0.002049274,0.5858336,0.00004629517,0.0001105813,0.000011564938,0.00029708503,0.00000511312,0.000007576407,0.000008346356,0.000022007227,0.3960604],"study_design_scores_gemma":[0.024557028,0.0023327556,0.97057325,0.00015099434,0.00020484671,0.0000011284498,0.000052098825,0.0012521283,0.000121811485,0.000080265636,0.000522229,0.00015144834],"about_ca_topic_score_codex":0.000028408913,"about_ca_topic_score_gemma":0.000059914495,"teacher_disagreement_score":0.39590895,"about_ca_system_score_codex":0.00027142957,"about_ca_system_score_gemma":0.0010271651,"threshold_uncertainty_score":0.6685962},"labels":[],"label_agreement":null},{"id":"W2090582753","doi":"10.3816/clm.2007.n.011","title":"Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma","year":2007,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Bone health and treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; University of Waterloo","funders":"","keywords":"Bone remodeling; Multiple myeloma; Medicine; Osteocalcin; Bone disease; Pathology; Internal medicine; Alkaline phosphatase; Osteoporosis; Biology; Biochemistry; Enzyme","score_opus":0.06308222886850288,"score_gpt":0.4007285747909416,"score_spread":0.3376463459224387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090582753","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.135595,0.85412,0.00015077647,0.000031769297,0.0008095419,0.00818697,0.00076527055,0.00004634822,0.00029429907],"genre_scores_gemma":[0.097143695,0.875376,0.025576865,0.00016490209,0.00020362157,0.00039834596,0.0008078011,0.00017790127,0.00015085949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99073446,0.00039992965,0.0062214313,0.0010997212,0.00082633906,0.0007181498],"domain_scores_gemma":[0.98951703,0.0038580731,0.0037207685,0.0017176493,0.00065373397,0.00053272396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003112958,0.0007148237,0.00589011,0.00017342978,0.00007940268,0.0000052281894,0.0004480958,0.00093150215,0.00002689082],"category_scores_gemma":[0.0011842655,0.0004223112,0.0023826472,0.00055702595,0.0011506035,0.000056648198,0.0002979172,0.00044146797,0.000006146272],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074429465,0.0031857404,0.016019046,0.03436456,0.0019479396,0.00001877284,0.0000068540826,1.2317752e-8,2.6136064e-7,0.000033599874,0.00014632962,0.9368339],"study_design_scores_gemma":[0.02024328,0.0026840654,0.7057288,0.0106595,0.009586039,0.000014260388,0.000034643956,0.000022269629,0.000026638345,0.000022994036,0.25057158,0.00040589817],"about_ca_topic_score_codex":0.000034134635,"about_ca_topic_score_gemma":0.00000458099,"teacher_disagreement_score":0.93642807,"about_ca_system_score_codex":0.00009374976,"about_ca_system_score_gemma":0.0007812823,"threshold_uncertainty_score":0.99982285},"labels":[],"label_agreement":null},{"id":"W2091115695","doi":"10.3816/clm.2009.n.008","title":"Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter Study","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; University Health Network","funders":"Leukemia and Lymphoma Research; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Clinical significance; Fluorescence in situ hybridization; Macroglobulinemia; Waldenstrom macroglobulinemia; Internal medicine; Gastroenterology; Biology; Monoclonal gammopathy of undetermined significance; Abnormality; In situ hybridization; Pathology; Medicine; Multiple myeloma; Antibody; Chromosome; Immunology; Genetics; Gene; Monoclonal; Gene expression; Lymphoma; Monoclonal antibody","score_opus":0.035326875047981744,"score_gpt":0.382843954020466,"score_spread":0.34751707897248424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091115695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574107,0.00041724608,0.000025605854,0.00067898445,0.00023072738,0.0020007344,0.000006459758,0.00009391214,0.0008052776],"genre_scores_gemma":[0.99682826,0.00014060066,0.0015778627,0.00063165295,0.00032353293,0.000052667958,0.000015780348,0.00003806674,0.00039156835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953869,0.00033005286,0.001905518,0.00081817753,0.00085273583,0.00070658774],"domain_scores_gemma":[0.996721,0.0013366768,0.00029700447,0.000935682,0.00034677904,0.000362842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013716395,0.00031247642,0.0010497549,0.00020323691,0.00004796731,0.000022480037,0.00035739664,0.0003482667,0.0000864293],"category_scores_gemma":[0.0054330034,0.00026966239,0.0002905899,0.0006702333,0.00031124306,0.000110215784,0.00014715358,0.00039625092,0.00018015073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037078476,0.0078076557,0.5573222,0.00015982587,0.000090715934,0.0027935267,0.0003970852,0.000014282657,0.00037531074,0.000043432145,0.00063247763,0.42665562],"study_design_scores_gemma":[0.044349696,0.003648037,0.93869495,0.00051189185,0.00012650609,0.00028348988,0.00030471306,0.010582124,0.00057345594,0.000137814,0.0005535382,0.0002337942],"about_ca_topic_score_codex":0.0002142582,"about_ca_topic_score_gemma":0.00010431792,"teacher_disagreement_score":0.42642182,"about_ca_system_score_codex":0.0031008555,"about_ca_system_score_gemma":0.0026664976,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W2105407688","doi":"10.3816/clm.2005.n.034","title":"Evolving Role of Stem Cell Transplantation in Multiple Myeloma","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Thalidomide; Melphalan; Multiple myeloma; Oncology; Transplantation; Internal medicine; Lenalidomide; Bortezomib; Prednisone; Hematopoietic stem cell transplantation; Surgery","score_opus":0.08757526195142284,"score_gpt":0.394048972723216,"score_spread":0.30647371077179314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105407688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017952025,0.9753283,0.0000099645895,0.000021479822,0.00023048827,0.0025112487,0.00026943427,0.0001007622,0.0035762845],"genre_scores_gemma":[0.04550906,0.9507443,0.0012215073,0.00003999064,0.00051215757,0.00026278227,0.0007195469,0.00016905114,0.0008216212],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99265534,0.00080861925,0.0034439778,0.0012207932,0.00090333936,0.0009679081],"domain_scores_gemma":[0.9941766,0.0028340244,0.00094349624,0.0011107315,0.00022028742,0.00071482203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010599544,0.0008642909,0.0044059055,0.00069430575,0.0000905099,0.000039390674,0.0005378397,0.0011808629,0.00023820064],"category_scores_gemma":[0.0002925809,0.000703685,0.0017831108,0.00079479587,0.00029824293,0.00018803036,0.00013826825,0.00069388514,0.0005896151],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048097872,0.0016721771,0.012053388,0.0114752455,0.00033426762,0.00073665596,0.00009192278,4.675402e-7,0.000008177344,0.000012246231,0.000103189166,0.9730313],"study_design_scores_gemma":[0.015745044,0.0013636802,0.22365709,0.02759549,0.0024225167,0.00062726694,0.00013928226,0.0005737055,0.00012968334,0.00002560561,0.7266606,0.0010600408],"about_ca_topic_score_codex":0.00012874504,"about_ca_topic_score_gemma":0.000101893485,"teacher_disagreement_score":0.9719712,"about_ca_system_score_codex":0.00058433606,"about_ca_system_score_gemma":0.0014574302,"threshold_uncertainty_score":0.9995414},"labels":[],"label_agreement":null},{"id":"W2106379961","doi":"10.3816/clm.2008.n.051","title":"Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment","year":2008,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Doxorubicin; Internal medicine; Renal function; Chemotherapy; Materials science","score_opus":0.030798670057492043,"score_gpt":0.3048801949785689,"score_spread":0.27408152492107685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106379961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964678,0.00021158469,0.000013341949,0.00019902964,0.00019892857,0.0024133807,0.000039964318,0.00013527912,0.00032065966],"genre_scores_gemma":[0.9974542,0.00022693611,0.00071645255,0.00027478964,0.00018384229,0.00011071996,0.00035881455,0.00008893031,0.0005852719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946576,0.0004882252,0.0016926398,0.0012011797,0.0009272443,0.0010331108],"domain_scores_gemma":[0.99653935,0.0012902803,0.00032422636,0.0007655474,0.00022757289,0.0008530326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006980709,0.0005716755,0.0012797321,0.0004697544,0.00022972528,0.000027977367,0.00018982723,0.00050856295,0.00015365853],"category_scores_gemma":[0.0013623128,0.00040262126,0.00017907092,0.00082118285,0.00052405824,0.00023220509,0.00018134747,0.00063281215,0.00010107396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119654484,0.00520286,0.7860438,0.00005408254,0.00024032602,0.002627407,0.00020168202,0.0000130846,0.000089981375,0.00000394635,0.00021096018,0.085657366],"study_design_scores_gemma":[0.12949337,0.010905318,0.8566469,0.0004023163,0.000090553374,0.0001848893,0.000047307825,0.001040971,0.00006639273,0.00000564644,0.00074404746,0.00037226317],"about_ca_topic_score_codex":0.00035884953,"about_ca_topic_score_gemma":0.00048152122,"teacher_disagreement_score":0.085285105,"about_ca_system_score_codex":0.0009587273,"about_ca_system_score_gemma":0.000958304,"threshold_uncertainty_score":0.9998426},"labels":[],"label_agreement":null},{"id":"W2114319427","doi":"10.3816/clm.2006.n.030","title":"Late Clinically Silent Perforation of Intestinal Non-Hodgkin's Lymphoma","year":2006,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Positron emission tomography; Medicine; Perforation; Lymphoma; Chemotherapy; Radiology; Abscess; Nuclear medicine; Pathology; Surgery","score_opus":0.02568037654029906,"score_gpt":0.32988548373048077,"score_spread":0.3042051071901817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114319427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98510855,0.0003393269,0.00017661508,0.0010564787,0.0007279639,0.0007776921,0.000029900364,0.00016010039,0.011623349],"genre_scores_gemma":[0.9904782,0.0001855142,0.005546205,0.0009736433,0.0011857408,0.000100145226,0.00020701678,0.00007190952,0.0012516158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99449265,0.00021295102,0.0029861536,0.00095142575,0.0007258739,0.0006309634],"domain_scores_gemma":[0.99572325,0.0014039279,0.00087404903,0.0010163086,0.0005336478,0.0004488381],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011906308,0.0005098689,0.0014091674,0.00017208669,0.00014849378,0.000051660805,0.0003038506,0.0004869941,0.00023776312],"category_scores_gemma":[0.0008684817,0.00041398962,0.0009586938,0.00042988846,0.0005549441,0.00016574842,0.00018599752,0.00013552266,0.00051588827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001395506,0.0057491497,0.6815372,0.00009117973,0.00020491135,0.00038775045,0.000037669044,0.0000124339285,0.0005094931,0.0006739907,0.0048818113,0.30451888],"study_design_scores_gemma":[0.013603717,0.00394737,0.96957344,0.00041699628,0.000491553,0.0002523048,0.000040251463,0.0016437613,0.0032555982,0.0007066485,0.0056921546,0.00037617848],"about_ca_topic_score_codex":0.00034406834,"about_ca_topic_score_gemma":0.000026214368,"teacher_disagreement_score":0.3041427,"about_ca_system_score_codex":0.00034492853,"about_ca_system_score_gemma":0.00081959995,"threshold_uncertainty_score":0.9998312},"labels":[],"label_agreement":null},{"id":"W2118477722","doi":"10.3816/clm.2009.n.038","title":"Biomarkers and Prognosis in Malignant Lymphomas","year":2009,"lang":"en","type":"article","venue":"Clinical Lymphoma & Myeloma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Boehringer Ingelheim","keywords":"Hematology; Lymphoma; Medicine; Internal medicine; Follicular lymphoma; Oncology; Hodgkin lymphoma; Mantle cell lymphoma; Pathology","score_opus":0.032543491852764624,"score_gpt":0.33770214878561705,"score_spread":0.30515865693285243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118477722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98354435,0.0023347216,0.0000024704868,0.0054577426,0.0002327188,0.0007958399,0.000008289968,0.00014066006,0.00748322],"genre_scores_gemma":[0.99378234,0.000993103,0.0015767738,0.0030620822,0.00020782779,0.00008263886,0.000031108466,0.00003089003,0.00023320716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968392,0.0001480478,0.0011364998,0.00088891695,0.00036268926,0.0006246216],"domain_scores_gemma":[0.9982285,0.00043406425,0.00017964219,0.00049653975,0.00008149755,0.00057974015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006443822,0.00039110193,0.00092553947,0.00022139774,0.0000927494,0.00006102616,0.00014626015,0.0003477122,0.00008485679],"category_scores_gemma":[0.00037323087,0.00030658854,0.00033190037,0.0004576032,0.00026481602,0.00013278799,0.00007924238,0.00008476995,0.00013280673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004287619,0.0019675589,0.5607663,0.00001717298,0.00010917259,0.0011501136,0.000041713727,6.857977e-8,0.00009287207,0.0007752168,0.0012942267,0.43335685],"study_design_scores_gemma":[0.01204841,0.0019509739,0.9765552,0.0003350424,0.00018512846,0.0007359787,0.00006860287,0.00013088496,0.0010780635,0.0007346635,0.0058568595,0.00032017886],"about_ca_topic_score_codex":0.000076991775,"about_ca_topic_score_gemma":0.000019154315,"teacher_disagreement_score":0.43303668,"about_ca_system_score_codex":0.00029532373,"about_ca_system_score_gemma":0.00029467634,"threshold_uncertainty_score":0.9999386},"labels":[],"label_agreement":null},{"id":"W2124433242","doi":"10.3816/clm.2009.n.019","title":"Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia","year":2009,"lang":"en","type":"review","venue":"Clinical Lymphoma & Myeloma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Proteasome inhibitor; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Peripheral neuropathy; Lymphoma; Endocrinology; Biology","score_opus":0.1287236890803222,"score_gpt":0.4669914693417026,"score_spread":0.3382677802613804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124433242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029509878,0.98589456,0.000002390747,0.00018992549,0.001102448,0.0031433,0.00007411447,0.00034526046,0.006297034],"genre_scores_gemma":[0.00022605201,0.9806894,0.0010597402,0.0010268084,0.0026618722,0.00022641073,0.00036513477,0.0003367251,0.013407821],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98673385,0.0012084974,0.006006856,0.0025042836,0.0015889013,0.001957637],"domain_scores_gemma":[0.98918515,0.0045273453,0.0012674934,0.0032601217,0.00029886648,0.0014610442],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0029782604,0.0015076216,0.008663293,0.0007916883,0.00012508992,0.000107844775,0.0014213836,0.0037289548,0.0010702738],"category_scores_gemma":[0.006902487,0.0010818955,0.0026867841,0.0019081832,0.00083209306,0.00011817992,0.00059583137,0.0023951617,0.0032655606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012506642,0.0012458643,0.00006389017,0.0091761,0.00032412595,0.02010521,0.000018038458,1.7751863e-7,1.6950881e-7,0.000039818795,0.015165113,0.95261085],"study_design_scores_gemma":[0.025008067,0.0017387504,0.0012014821,0.031021189,0.0012751768,0.0072903195,0.000016917375,0.00020394941,0.0000010017127,0.00005352185,0.9311824,0.0010072525],"about_ca_topic_score_codex":0.00022757932,"about_ca_topic_score_gemma":0.00012495734,"teacher_disagreement_score":0.9516036,"about_ca_system_score_codex":0.028717088,"about_ca_system_score_gemma":0.06279638,"threshold_uncertainty_score":0.99990636},"labels":[],"label_agreement":null}]}